Glycanostics develops a diagnostic test utilizing glycan biomarkers for the early detection of prostate cancer, providing high accuracy in identifying the disease at its initial stages. This technology addresses the challenge of late-stage diagnosis, which often leads to increased treatment costs and poorer patient outcomes.
Funding
$2.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Prostate cancer is often diagnosed at a late stage, leading to increased treatment costs and poorer patient outcomes. Current diagnostic methods lack the accuracy needed for reliable early detection.
Solution
Glycanostics is developing a diagnostic test that utilizes glycan biomarkers to detect prostate cancer at its early stages with high accuracy. The test aims to improve early detection rates, enabling timely intervention and potentially reducing treatment costs and improving patient outcomes. By focusing on glycan biomarkers, Glycanostics offers a novel approach to prostate cancer diagnostics, addressing the limitations of existing methods.
Target Audience
The primary target audience includes healthcare providers, urologists, and diagnostic laboratories involved in prostate cancer screening and diagnosis.
Features
- Utilizes glycan biomarkers for prostate cancer detection
- Designed for early-stage diagnosis
- Aims for high accuracy in identifying prostate cancer